Nasdaq
$1.13▼ 4.24%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.3MShares out 3.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
22- 10.9Pre-market26.10.09 19:02RWOther#●●●#●●●
Alzamend Neuro, Inc.
Alzamend Neuro, Inc. has officially requested the withdrawal of its Form S-1 registration statement (File No. 333-298490), originally filed on August 21, 2026, which sought to register up to 98,388,305 shares of common stock for resale. The company decided to withdraw the filing after being advised by the SEC that the transaction structure, which was intended to function as an equity line of credit, could not be declared effective. The company confirms that no securities have been or will be sold under this registration statement.…more
$1.13-4.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.29Pre-market26.09.29 19:308-KKey event
Alzamend Neuro, Inc.
Alzamend Neuro presented pharmacokinetic imaging results for its clinical candidate AL001 at the ISMRT conference, based on its Phase 1/2A trial. While the study indicated trends of improved brain delivery compared to traditional lithium salts, the differences were not statistically significant, necessitating further testing in subsequent patient cohorts.…more
$1.13-4.24%vs prev closeView filingShare - 9.10After-hours26.09.11 05:3010-QEarnings
Alzamend Neuro, Inc.
Alzamend Neuro reported a net loss of $3,027,002 for the quarter ended July 31, 2026. During the period, the company raised capital through the issuance of common stock and Series D convertible preferred stock, ending the quarter with $7,591,444 in cash.…more
$1.13-4.24%vs prev closeView filingShare
21 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.16Pre-market26.09.16 21:04#●●●
Alzamend Neuro Regains Nasdaq Compliance
Alzamend Neuro has received notification from Nasdaq that it has regained compliance with the minimum stockholders' equity requirement. This development resolves the company's listing status issue and closes the matter.…more
$1.13-4.24%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.10After-hours26.09.11 06:23
●●●●●●●● ●●●●● ●●●●●●
Alzamend Neuro reported a Q1 loss per share of $0.68, missing analyst expectations, while posting zero revenue for the quarter. The company continues to face financial challenges with no significant improvement in top-line growth.…more
$1.13-4.24%vs prev closeShareBenzinga - 8.21After-hours26.08.22 05:51
●●●●●●●● ●●●●● ●●●●●●
Alzamend Neuro has filed a prospectus with the SEC for the potential resale of up to 98.4 million common shares by selling stockholders. This filing raises concerns regarding potential share dilution and increased selling pressure on the stock.…more
$1.13-4.24%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report